Follow us

Nanomedicine
For Precision
Radiotherapy

Nanomedicine
For Precision
Radiotherapy

Nanomedicine
For Precision
Radiotherapy

Nanomedicine
For Precision
Radiotherapy

Nanomedicine
For Precision
Radiotherapy

Nanomedicine
For Precision
Radiotherapy

AGuIX®: an innovative nanodrug with the aim to improve radiotherapy treatment of cancer

NH Theraguix

EVENTS

NH TherAguix staff member awarded with a Ph.D. prize

NH TherAguix is pleased to announce that Fabien Boux which joined the Clinical Development Unit as Biomedical Engineer in January, was awarded with the Ph. D. prize 2020 of the Société Française de Résonance Magnétique en Biologie et Médecine ("SFRMBM"). [button...

PRESS RELEASE

SCIENTIFIC PUBLICATIONS

Géraldine LE DUC, NH Theraguix

60% of cancer patients are treated by radiotherapy with an expected increase of 16% by 2025

However 48% of cancer patients receiving radiotherapy do not survive mainly related to unwanted damage of surrounding tissues and organs imposing dose limitations

In this context of high unmet medical need,
AGuIX® drug has the potential
to overcome these limitations

AGuIX® is an easy-to-use innovative drug that has the potential to fit well with multiple radiotherapy protocols and to be applicable to a wide range of cancer indications

AGuIX® drug selectively accumulates in tumors based on its small size after intravenous administration and excess is rapidly eliminated through the kidneys

AGuIX® drug concentrates numerous gadolinium elements in its structure that provide:

  • Imaging property by magnetic resonance imaging (MRI)
  • Therapeutic activity through its radioenhancing property

Thanks to this combination of pharmacological properties, the AGuIX® drug could offer
a better lifespan and quality of life for patients affected by cancer